Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brelovitug vs Bulevirtide in Chronic Hepatitis Delta Infection
NCT07200908Phase 3Recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of brelovitug in chronic hepatitis D, sponsored by Mirum Pharmaceuticals, Inc.. Started Aug 2025; status: recruiting.
02
Drugs
brelovitug
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07200908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200908.